Omalizumab for Pediatric Cutaneous Mastocytosis: Case Report and Review.

IF 1.2 4区医学 Q3 DERMATOLOGY

Pediatric Dermatology Pub Date : 2025-10-08 DOI:10.1111/pde.70038

Janis Chang, Aliyah King, Adam Byrne, Carmen Liy-Wong

引用次数: 0

Abstract

We report an 11-month-old boy with diffuse cutaneous mastocytosis whose severe pruritus and steroid dependence resolved following off-label treatment with omalizumab. A literature review identified five additional pediatric cases in which omalizumab led to complete symptom resolution in an average of 2 months and permitted discontinuation of systemic steroids. Although limited by the small sample size and lack of high-quality data, omalizumab presents as a well-tolerated and potentially effective steroid-sparing agent for pediatric cutaneous mastocytosis.

查看原文本刊更多论文

Omalizumab治疗儿童皮肤肥大细胞增多症：病例报告和回顾。

我们报告了一个11个月大的男孩，患有弥漫性皮肤肥大细胞增多症，其严重瘙痒和类固醇依赖在使用omalizumab治疗后得到解决。一项文献综述确定了另外5例小儿病例，其中omalizumab平均在2个月内导致症状完全缓解，并允许停用全体性类固醇。尽管受样本量小和缺乏高质量数据的限制，omalizumab作为一种耐受性良好且潜在有效的类固醇保留剂治疗儿童皮肤肥大细胞增多症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pediatric Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

6.70%

发文量

269

审稿时长

1 months

期刊介绍： Pediatric Dermatology answers the need for new ideas and strategies for today''s pediatrician or dermatologist. As a teaching vehicle, the Journal is still unsurpassed and it will continue to present the latest on topics such as hemangiomas, atopic dermatitis, rare and unusual presentations of childhood diseases, neonatal medicine, and therapeutic advances. As important progress is made in any area involving infants and children, Pediatric Dermatology is there to publish the findings.